SHERIDAN, WYOMING – May 7, 2025 – Olympus Corporation, a global MedTech leader, has announced its most successful "Dress in Blue" campaign yet, marking a new milestone in its commitment to Colorectal Cancer Awareness Month. With 6,810 employees from across the globe participating, this year’s campaign underscores Olympus’ ongoing dedication to reducing cancer-related deaths through awareness and early detection initiatives.

SHERIDAN, WYOMING – May 7, 2025 – Baxter International Inc. (NYSE:BAX), a global leader in medical technologies, has announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. This dividend is payable on July 1, 2025, to shareholders of record as of May 30, 2025. The indicated annual dividend rate is set at $0.68 per share.

SHERIDAN, WYOMING – May 7, 2025 – Baxter International Inc. (NYSE: BAX), a leading global medtech company, has announced its first-quarter financial results for 2025, reflecting solid performance driven by strategic transformation initiatives. The company’s results indicate continued growth across its core business segments, positioning Baxter for long-term value creation despite global macroeconomic uncertainty.

Strategic Transformation and Focus on Execution

SHERIDAN, WYOMING – May 7, 2025 – Baxter International Inc. (NYSE: BAX), a global leader in medical technology, will host a conference call on Thursday, May 8, 2025, at 7:30 a.m. Central Time to discuss its first-quarter 2025 financial results. Investors, analysts, and other stakeholders are invited to participate in the call by pre-registering through the provided link to receive the necessary call-in information.

SHERIDAN, WYOMING – May 7, 2025 – Baxter International Inc., a global leader in advancing surgical innovation, has announced the launch of its Hemopatch Sealing Hemostat with room temperature storage at a symposium in Vienna, Austria. This new product evolution significantly improves accessibility for surgeons, offering a practical and effective solution for controlling bleeding and preventing leakage during surgery. The product is now available for order throughout Europe, marking a key step forward in Baxter’s ongoing commitment to enhancing patient care.

SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW), a global leader in structural heart innovation, will announce its operating results for the first quarter ending March 31, 2025, after market close on Wednesday, April 23, 2025. The company will then host a conference call at 5:00 p.m. ET that same day to discuss these results in detail, providing insights into its financial performance and future strategic direction.

Conference Call Details and Participation

SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW) today unveiled new eight-year clinical data, confirming the exceptional long-term performance of its RESILIA tissue technology in aortic surgical valves. The data demonstrate significant improvements in patient outcomes, reinforcing the company's leadership in structural heart solutions.

SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW), a global leader in structural heart innovation, has announced its financial results for the first quarter ended March 31, 2025. The company delivered impressive growth across key product categories, including Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT), positioning itself for continued success in the structural heart market.

SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW) has announced the U.S. Food and Drug Administration (FDA) approval of its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for use in patients with asymptomatic severe aortic stenosis (AS). This groundbreaking approval marks the first-ever FDA authorization for TAVR in asymptomatic patients, potentially transforming the treatment landscape for those with this critical condition.

SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW) has announced its participation in the highly anticipated BofA Securities 2025 Health Care Conference, scheduled for Tuesday, May 13, 2025. The company's leadership, including CEO Bernard Zovighian and CFO Scott Ullem, will take part in a fireside chat at 10:40 a.m. Pacific Time. The discussion will be accessible to investors and healthcare professionals through a live webcast available on the Edwards Lifesciences investor relations website at http://ir.edwards.com.